Welcome to our dedicated page for Amplia Therapeutics news (Ticker: INNMF), a resource for investors and traders seeking the latest updates and insights on Amplia Therapeutics stock.
Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for cancer and fibrosis, led by narmafotinib. Company news centers on clinical development of narmafotinib in fibrotic cancers, including pancreatic and ovarian cancer, where updates describe combination studies with standard-of-care chemotherapy, trial data presentations, safety and response analyses, and biomarker work.
Recurring announcements also cover preclinical research in KRAS-mutated cancer models, GMP manufacturing and drug-supply scale-up for narmafotinib, patent and regulatory communications, quarterly activities and cash-flow reporting, and the company’s ASX listing and OTCQB quotation under INNMF.
Amplia Therapeutics (OTCQB: INNMF, ASX: ATX) is initiating a Phase 2b, registration-enabling study of narmafotinib in advanced pancreatic cancer, using a new daily dosing regimen with gemcitabine and Abraxane.
The 12-patient first stage, run at 3-4 Australian sites, targets safety, tolerability, PK and efficacy, with enrolment expected by Q4 2026 and key assessments by Q2 2027. Narmafotinib holds FDA orphan drug and fast track designations.
Amplia Therapeutics (OTCQB:INNMF) and ANZGOG have agreed to an investigator-initiated clinical study (PRROSE) testing narmafotinib with carboplatin and paclitaxel in high-grade serous ovarian cancer patients who show poor response to up-front platinum chemotherapy.
The trial will enroll ~15–20 patients, focus on safety and whether narmafotinib increases eligibility for successful interval debulking surgery, and will collect extensive tissue and blood biomarkers.
Amplia Therapeutics (OTCQB:INNMF) presented mature data from the ACCENT trial in metastatic pancreatic cancer at AACR on April 22, 2026. The oral presentation reported a manageable toxicity profile and independent reads showing 5 confirmed CRs (8% of 64 patients), an overall response rate of 36%, a disease control rate of 70%, median OS 11.1 months and median PFS 7.7 months.
The company said subsequent trials will use daily narmafotinib dosing and plan a pivotal study based on ACCENT findings.
Amplia Therapeutics (OTCQB:INNMF) reported updated ACCENT Phase 1b/2a data in advanced pancreatic cancer showing a median overall survival (mOS) of 11.1 months and five confirmed complete responses (CRs) at the 400 mg narmafotinib dose, a CR rate of 7.8% (5/64).
Independent central RECIST 1.1 review raised CRs by four patients, updated ORR to 35.9% (23/64), found no additional toxicity, and the Company will present results at AACR April 17-22, 2026.
Amplia Therapeutics (OTCQB:INNMF) reported preclinical poster data on March 6, 2026 showing its FAK inhibitor narmafotinib enhances the activity of kRAS inhibitors across pancreatic, lung and ovarian cancer models. The data suggest narmafotinib can block resistance pathways and may improve efficacy and durability of kRAS therapies.
The findings were presented at the AACR Special Conference: RAS Oncogenesis and Therapeutics; a copy of the poster is available from the company.
Amplia Therapeutics (OTCQB:INNMF) opened two US sites for the AMPLICITY pancreatic cancer trial: University of California, Irvine and The Cleveland Clinic.
These join two Australian sites (Epworth Hospital and Genesis Care). Three more US sites are expected to open in the coming weeks as recruitment continues for narmafotinib plus FOLFIRINOX.
Amplia Therapeutics (OTCQB: INNMF; ASX: ATX) reported clinical and financial progress for the quarter ending 31 December 2025, highlighting a 35% confirmed objective response rate (19/55) in the ACCENT trial and initiation of the Phase 1b/2a AMPLICITY trial combining narmafotinib with FOLFIRINOX.
Other highlights: positive FDA feedback on dose optimisation, a US patent extending protection to at least 2040, successful OTCQB uplisting, advancement of a Next & Bio preclinical collaboration, and a closing cash position of $31.5 million.
Amplia Therapeutics (OTCQB:INNMF) announced successful completion of a large-scale manufacture campaign of narmafotinib, producing approximately 13 kg of API to required purity and quality on Jan 22, 2026. The campaign moved production from an R&D facility to a commercial GMP environment, delivering reported production efficiencies and cost savings.
The ~13 kg API will be converted into oral capsules to supply Amplia’s pancreatic cancer trials and other planned studies, supporting Phase‑3 readiness and the company’s clinical development pipeline.
Amplia Therapeutics (ASX:ATX; OTCQB:INNMF) presented interim Phase 2a ACCENT trial data in metastatic pancreatic cancer at the ASCO Gastrointestinal Cancer Symposium on Jan 9, 2026, announced Jan 12, 2026. The poster reported updated progression-free survival (PFS) of 7.7 months versus 5.5 months for gemcitabine plus Abraxane alone, and an overall response rate (ORR) of 35% (rising to 42% including unconfirmed responses). Narmafotinib, a FAK inhibitor given with standard chemotherapy, was described as well tolerated with an adverse effect profile similar to chemotherapy alone. A copy of the poster is available on the company website.
Amplia Therapeutics (OTCQB:INNMF) announced that its CMO, Dr Jason Lickliter, will present a poster at the ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8-10, 2026.
The poster, titled "Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results", will present updated data from the ongoing ACCENT trial. The full abstract will be published at 5:00 PM US ET on January 5, 2026.
Poster details: Friday, January 9, 2026, 11:30 AM–1:00 PM US PT, Level 1 West Hall Moscone West, Poster K5.